Market Update (NYSE:MRK): Merck to Present New Data from Clinical Studies Evaluating Investigational Hepatitis C Treatment Grazoprevir/Elbasvir (MK-5172/MK-8742) at the 65th American Association for the Study of Liver Diseases Annual Meeting

[Business Wire] – Merck , known as MSD outside the United States and Canada, today announced that new data from clinical studies of the company’s investigational, oral, once-daily, fixed-dose combination chronic hepatitis C . . . → Read More: Market Update (NYSE:MRK): Merck to Present New Data from Clinical Studies Evaluating Investigational Hepatitis C Treatment Grazoprevir/Elbasvir (MK-5172/MK-8742) at the 65th American Association for the Study of Liver Diseases Annual Meeting Similar Articles: Stock Update (NYSE:MRK): Merck Presents First Phase 3 Data in Japanese Patients for Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes Company Update (NYSE:MRK): Merck Announces Third-Quarter 2014 Dividend Market Update: Merck & Co Inc (NYSE:MRK) – Merck to Hold Investor Briefing at Boston Research Facility
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.